Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Registration Trials for Olaratumab and Doxorubicin for STS

November 8th 2016

FDA Approval of Olaratumab + Doxorubicin for STS

November 8th 2016

Multidisciplinary Care of STS

November 8th 2016

Disease State: Advanced Soft Tissue Sarcoma

November 8th 2016

Immunotherapy, MEK Inhibitor Combo Effective for BRAF Wild-Type Melanoma

November 8th 2016

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Dr. Christian Blank on Combining Immunotherapy Agents in High-Risk Melanoma

November 8th 2016

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.

Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma

November 8th 2016

Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.

Dr. Ryan Sullivan on Treating BRAF-Mutant Patients With Melanoma

November 8th 2016

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.

Atezolizumab Combos Highly Effective for Advanced Melanoma

November 7th 2016

The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with BRAF-mutant unresectable melanoma.

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma

November 4th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

The Future of Non-Driver Lung Adenocarcinoma

October 31st 2016

Cost Considerations in Non-Driver NSCLC Management

October 31st 2016

Nintedanib in Lung Adenocarcinoma: Managing Toxicities

October 31st 2016

Practical Considerations With Nintedanib in Lung Adenocarcinoma

October 31st 2016

Practical Implications of the LUME-Lung 1 Findings

October 31st 2016

Lung Adenocarcinoma: Patient Selection With Ramucirumab vs Nintedanib

October 31st 2016

Differentiating Among Anti-VEGF Therapies in Lung Adenocarcinoma

October 31st 2016

Non-Driver NSCLC: Clinical Decisions in Rapidly Progressing Disease

October 31st 2016

PD-L1 Status in Second-Line Lung Adenocarcinoma

October 31st 2016

Options in Second-Line Non-Squamous NSCLC

October 31st 2016